A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma Clinical Trial

Official title:
A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Status Completed

Clinical Trial Summary

This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in participants with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Esophageal Neoplasms
Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical Trial Details

NCT number	NCT02340975
Study type	Interventional
Source	MedImmune LLC
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	March 31, 2015
Completion date	April 29, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04098796` - PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2
Completed	`NCT03849469` - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT03752398` - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)	Phase 1
Recruiting	`NCT05994456` - Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer	Phase 2
Recruiting	`NCT05482893` - PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)	Phase 1/Phase 2
Active, not recruiting	`NCT05941481` - Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ	Phase 2
Completed	`NCT03517488` - A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors	Phase 1
Completed	`NCT04192734` - Retrospective Study of Ramucirumab and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
Not yet recruiting	`NCT05218148` - SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma	Phase 2